image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 4.45
-2.56 %
$ 1.71 B
Market Cap
109.25
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GDRX stock under the worst case scenario is HIDDEN Compared to the current market price of 4.45 USD, GoodRx Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GDRX stock under the base case scenario is HIDDEN Compared to the current market price of 4.45 USD, GoodRx Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GDRX stock under the best case scenario is HIDDEN Compared to the current market price of 4.45 USD, GoodRx Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GDRX

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
792 M REVENUE
5.61%
65.8 M OPERATING INCOME
343.81%
16.4 M NET INCOME
284.82%
163 K OPERATING CASH FLOW
-99.88%
-70.3 M INVESTING CASH FLOW
-26.15%
-337 M FINANCING CASH FLOW
-101.62%
199 M REVENUE
1.71%
18.2 M OPERATING INCOME
-10.91%
6.74 M NET INCOME
69.99%
44.7 M OPERATING CASH FLOW
-48.49%
-16.6 M INVESTING CASH FLOW
-4.95%
-3.53 M FINANCING CASH FLOW
97.95%
Balance Sheet GoodRx Holdings, Inc.
image
Current Assets 659 M
Cash & Short-Term Investments 448 M
Receivables 161 M
Other Current Assets 50.1 M
Non-Current Assets 729 M
Long-Term Investments 0
PP&E 40.5 M
Other Non-Current Assets 688 M
32.30 %11.59 %3.61 %2.91 %49.59 %Total Assets$1.4b
Current Liabilities 124 M
Accounts Payable 14.1 M
Short-Term Debt 10.6 M
Other Current Liabilities 99.1 M
Non-Current Liabilities 540 M
Long-Term Debt 46 M
Other Non-Current Liabilities 493 M
14.94 %6.94 %74.38 %Total Liabilities$663.4m
EFFICIENCY
Earnings Waterfall GoodRx Holdings, Inc.
image
Revenue 792 M
Cost Of Revenue 48.2 M
Gross Profit 744 M
Operating Expenses 678 M
Operating Income 65.8 M
Other Expenses 49.5 M
Net Income 16.4 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00792m(48m)744m(678m)66m(49m)16mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
93.91% GROSS MARGIN
93.91%
8.31% OPERATING MARGIN
8.31%
2.07% NET MARGIN
2.07%
2.26% ROE
2.26%
1.18% ROA
1.18%
2.69% ROIC
2.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis GoodRx Holdings, Inc.
image
160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020192019202020202021202120222022202320232024202420252025
Net Income 16.4 M
Depreciation & Amortization 69.5 M
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 0
Others -16.2 M
Free Cash Flow 163 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets GoodRx Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for GDRX of $9.62 , with forecasts ranging from a low of $9 to a high of $10 .
GDRX Lowest Price Target Wall Street Target
9 USD 102.25%
GDRX Average Price Target Wall Street Target
9.62 USD 116.29%
GDRX Highest Price Target Wall Street Target
10 USD 124.72%
Price
Max Price Target
Min Price Target
Average Price Target
1010998877665544Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership GoodRx Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
565 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business out. businesswire.com - 3 weeks ago
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services. zacks.com - 3 weeks ago
GoodRx Introduces New E-commerce Experience for Retail Pharmacies SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced a new e-commerce experience for retail pharmacies that improves how consumers get their medications via the GoodRx platform. The company is launching the experience with Midwest-based retailer Hy-Vee. Now, when a person searches for their medication on GoodRx and selects Hy-Vee as their preferred pharmacy, the system will check for medication inventory, validate. businesswire.com - 4 weeks ago
GoodRx: Great Value For Patient Investors (Upgrade) GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target for private equity deals as public equities become less appealing. The company's new CEO is driving a wholesale change in business strategy, chasing relationships directly with pharmaceutical manufacturers. seekingalpha.com - 1 month ago
GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and man. businesswire.com - 1 month ago
GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today released a new report, The Prescription Drug Gender Divide, detailing how women shoulder a significantly greater out-of-pocket cost burden than men. The data shows that in 2024, women spent $8.8 billion – or 30% – more than men on out-of-pocket prescription costs. Combined with the common responsibilities of managing a career, family planning, and caregiving, women are le. businesswire.com - 1 month ago
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million. benzinga.com - 2 months ago
GoodRx Holdings, Inc. (GDRX) Q4 2024 Earnings Call Transcript GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - Bank of America Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Fourth Quarter and Full Year 2024 Earnings Call. seekingalpha.com - 2 months ago
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 months ago
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago. zacks.com - 2 months ago
GoodRx Reports Fourth Quarter and Full Year 2024 Results SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA. businesswire.com - 2 months ago
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. zacks.com - 2 months ago
8. Profile Summary

GoodRx Holdings, Inc. GDRX

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.71 B
Dividend Yield 0.00%
Description GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Contact 2701 Olympic Boulevard, Santa Monica, CA, 90404 https://www.goodrx.com
IPO Date Sept. 23, 2020
Employees 738
Officers Mr. Romin Nabiey Chief Accounting Officer Ms. Aubrey Reynolds Director of Investor Relations Mr. Ryan Sullivan Chief Marketing Officer Mr. Trevor Bezdek Co-founder & Co-Chairman of the Board Ms. Wendy Barnes President, Chief Executive Officer & Director Mr. Nitin Shingate Chief Technology Officer Mr. Christopher A. McGinnis Chief Financial Officer & Treasurer Mr. Bansi Nagji President of Healthcare Mr. Douglas Joseph Hirsch Co-founder & Director Ms. Gracye Cheng Senior Vice President, General Counsel & Secretary